Drug Trial Radar · NCT02110147
Open-Label Study of Uridine Triacetate in Pediatric Patients With Hereditary Orotic Aciduria
Last checked: Nov 20, 2026Latest source record: Jul 31, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4
Actual
Start
Apr 2014
Primary completion
Dec 2014
Study completion Sep 8, 2016
Sponsor
- Lead sponsor
- Wellstat TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Apr 10, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 6 months, up to 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This protocol has two parts - the Main Study which is 42 days in length and the Treatment Extension which allows the patients who complete the Main Study to continue receiving treatment with uridine triacetate. The purpose of this study is to replace oral administration of uridine with oral administration of uridine triacetate in patients with hereditary orotic aciduria who have received (or would reasonably be expected to receive) clinical benefit from treatment with exogenous uridine. It is also to document the continued clinical benefit of exogenous uridine when patients are switched from oral administration of uridine to oral administration of uridine triacetate.
Conditions
- Hereditary Orotic Aciduria
Interventions
uridine triacetateDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Patients With Stable Predetermined Principal Hematologic ParametersTime frame: Days 28 and 42
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Children's Hospital of Michigan - Specialty Center Detroit
Detroit, Michigan
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, Pennsylvania
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.